A Critical Appraisal of Ticlopidine, a New Antiplatelet Agent: Effectiveness and Clinical Indications for Prophylaxis of Atherosclerotic Events

Archives of Internal Medicine

Volumn 152, Issue 7, 1992, Pages 1376-1380

  Haynes, R Brian ^a   Sandler, Robert S ^b   Larson, Eric B ^c   Pater, Joseph L ^d   Yatsu, Frank M ^e  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d QUEEN S UNIVERSITY   (Canada)

^e UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; TICLOPIDINE;

ATHEROSCLEROSIS; BLOOD CELL COUNT; DRUG EFFICACY; HEART INFARCTION; INTERMITTENT CLAUDICATION; MEDICAL LITERATURE; NEUTROPENIA; PERIPHERAL VASCULAR DISEASE; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT DISEASE; REVIEW; STROKE; TRANSIENT ISCHEMIC ATTACK;

ARTERIOSCLEROSIS; CEREBROVASCULAR DISORDERS; DIARRHEA; FEMALE; HUMAN; MALE; NEUTROPENIA; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; SUPPORT, NON-U.S. GOV'T; TICLOPIDINE;

EID: 0026632392     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.1992.00400190018006     Document Type: Review

References (21)

1. Anderson GI, Whisnant JP. A comparison of trends in mortality from stroke in the United States and Rochester, Minnesota. Stroke. 1982;13:804-809.
2. Secondary prevention of vascular disease by prolonged antiplatelet treatment: Antiplatelet Trialists’ Collaboration. BMJ. 1988;296:320-331.
3. FitzGerald GA. Dipyridamole. N Engl J Med. 1987;316:1247-1257.
4. Canadian Cooperative Study Group. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med. 1978;299:53-59.
5. Gent M, Blakely JA, Hachinski V, et al. A secondary prevention, randomized trial of suloctidil in patients with a recent history of thromboembolic stroke. Stroke. 1985;16:416-424.
6. Dyken ML. Anticoagulant and platelet-antiaggregating therapy in stroke and threatened stroke. Neurol Clin. 1983;1:223-242.
7. North American Symptomatic Carotid Endanterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med. 1991;325:445-453.
8. The EC/IC Bypass Study Group. Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke: results of an international randomized trial. N Engl J Med. 1985;313:1191-1200.
9. McTavish D, Faulds D, Goa KL. Ticlopidine: an updated review of its pharmacology and therapeutic use in platelet-dependent disorders. Drugs. 1990;40:238-259.
10. Hass WK, Easton JD, Adams HP, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high risk patients. N Engl J Med. 1989;321:501-507.
11. Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet. 1989;1:1215-1220.
12. Janzon L, Bergqvist D, Boberg J, et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication: effects of ticlopidine: results from STIMS, the Swedish Ticlopidine Multicentre Study. J Intern Med. 1990;227:301-308.
13. Balsano F, Rizzon P, Violi F, et al. Antiplatelet treatment with ticlopidine in unstable angina: a controlled multicenter clinical trial. Circulation. 1990;82:17-26.
14. Department of Clinical Epidemiology and Biostatistics, McMaster University. How to read clinical journals, V: to distinguish useful from useless or even harmful therapy. Can Med Assoc J. 1981;124:1156-1162.
15. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med. 1988;318:1728-1733.
16. Arcan JC, Blanchard J, Boissel JP, Panak E. Multicenter double-blind study of ticlopidine in the treatment of intermittent claudication and the prevention of its complications. Angiology. 1988;39:802-811.
17. Balsano F, Coccheri S, Libretti A, et al. Ticlopidine in the treatment of intermittent claudication: a 21-month double-blind trial. J Lab Clin Med. 1989;114:84-91.
18. Ticlopidine treatment reduces the progression of nonproliferative diabetic retinopathy: the TIMAD Study Group. Arch Ophthalmol. 1990;108:1577-1583.
19. Limet R, David JL, Magotteaux P, Larock MP, Rigo P. Prevention of aorta-coronary bypass graft occlusion: beneficial effect of ticlopidine on early and late patency rates of venous coronary bypass grafts: a double-blind study. J Thorac Cardiovasc Surg. 1987;94:773-783.
20. Castelli P, Basellini A, Agus GB, et al. Thrombosis prevention with ticlopidine after femoropopliteal thromboendarterectomy. Int Surg. 1986;71:252-255.
21. Saltiel E, Ward A. Ticlopidine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states. Drugs. 1987;34:222-262.